Survival analyses from the ZEBRA study - goserelin (Zoladex(TM)) versus CMF in premenopausal women with node-positive breast cancer

By Kaufmann M.   Jonat W.   Blamey R.   Cuzick J.   Namer M.   Fogelman I.   de Haes J.C.   Schumacher M.   Sauerbrei W.   on behalf of the Zoladex Early Breast Cancer Research Association ZEBRA Trialists' Group  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1711-1717

Elsevier

Access to resources Recommend Favorite

Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients - effect of adjuvant chemotherapy

By Poikonen P.   Saarto T.   Elomaa I.   Joensuu H.   Blomqvist C.  

European Journal of Cancer, Vol. 36, Iss. 1, 2000-01 ,pp. : 43-48

Elsevier

Access to resources Recommend Favorite

Systemic adjuvant treatment for premenopausal node-negative breast cancer

By Castiglione-Gertsch M.   Gelber R.D.   O'Neill A.   Coates A.S.   Goldhirsch A.  

European Journal of Cancer, Vol. 36, Iss. 4, 2000-03 ,pp. : 549-550

Elsevier

Access to resources Recommend Favorite

Optimizing Anthracycline Therapy for Node Positive Breast Cancer

By Cardoso F.   Atalay G.   Piccart M.J.  

American Journal of Cancer, Vol. 1, Iss. 4, 2002-01 ,pp. : 257-268

Adis International

Access to resources Recommend Favorite

Prognostic variables in node-negative and node-positive breast cancer - Introduction

By Gasparini G.  

Breast Cancer Research and Treatment, Vol. 51, Iss. 3, 1998-10 ,pp. : 193-194

Springer Publishing Company

Access to resources Recommend Favorite